FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

The FDA said Wednes­day that it is in­ves­ti­gat­ing “se­ri­ous risk of hema­to­log­ic ma­lig­nan­cy” fol­low­ing the ad­min­is­tra­tion of blue­bird bio’s Skysona, a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.